Background and Need for Legislation
In the United States, approximately 18,500 patients are
diagnosed with a life-threatening blood cancer or other
diseases that necessitate a blood stem cell transplant each
year. Only one quarter of individuals who are seeking a
transplant will be matched with a family member; the remaining
individuals must receive a transplant from a biologically
unrelated donor or umbilical cord blood unit (CBU).\1\ The C.W.
Bill Young Cell Transplantation program (CWBYCTP) supports the
process of identifying, matching, and facilitating the
distribution of bone marrow, peripheral blood stem cells, and
cord blood from biologically unrelated donors for patients who
necessitate blood stem cell transplants.\2\
---------------------------------------------------------------------------
\1\Health Resources & Services Administration, Report to Congress,
Fiscal Year 2024 Annual Progress Report on the C.W. Bill Young Cell
Transplantation Program and National Cord Blood Inventory Program,
(2024), https://bloodstemcell.hrsa.gov/sites/default/files/
bloodstemcell/about/legislation/fiscal-year-2024-annual-progress-
report.pdf.
\2\Id.
---------------------------------------------------------------------------
In 2005, the Stem Cell Therapeutic and Research Act was
signed into law, creating the C.W. Bill Young Cell
Transplantation Program to replace the National Bone Marrow
Donor Registry (NBMDR), established in 1987 through a
Congressionally-directed grant from the U.S. Department of the
Navy.\3\ This law directed the Secretary of HHS to collect and
store 150,000 units of ``high-quality and genetically diverse
cord blood'' for transplantation.\4\ It authorized contracting
with cord blood banks and created the National Cord Blood
Inventory (NCBI) to support and coordinate banking efforts.\5\
This program was amended and reauthorized in 2010, 2015, and
2021.\6\
---------------------------------------------------------------------------
\3\Stem Cell Therapeutic and Research Act of 2005, Pub. L. No. 109-
129, 119 Stat. 2005; see also Health Resources & Services
Administration, Legislation (Feb. 2026), https://
bloodstemcell.hrsa.gov/about/legislation.
\4\Government Accountability Office (GAO), National Cord Blood
Inventory: Practices for Increasing Availability for Transplants and
Related Challenges, GAO-12-23 at page 1 (Oct. 2011), https://
www.gao.gov/assets/gao-12-23.pdf.
\5\GAO, supra note 4.
\6\Health Resources & Services Administration, Legislation (Feb.
2026), https://bloodstemcell.hrsa.gov/about/legislation.
---------------------------------------------------------------------------
H.R. 5160, the Stem Cell Therapeutic and Research
Reauthorization Act of 2025, reauthorizes the C.W. Bill Young
Cell Transplantation program and the National Cord Blood
Inventory program through Fiscal Year 2031. Additionally, this
bill updates certain provisions to reflect current evidence-
based scientific and clinical practices.
Committee Action
On April 15, 2026, the Subcommittee on Health held a
legislative hearing on H.R. 5160. The title of the hearing was
``Healthier America: Legislative Proposals to Improve Public
Health.'' The Subcommittee received testimony from:
Jamie Ulmer, MA, President and CEO,
Healthcare Network
Rachel F. Brem, MD, FACR, FSBI, Co-Founder,
Chief Medical Officer, Brem Foundation to Defeat Breast
Cancer and Professor and Vice-Chair Emeritus, The
George Washington University
Holly Ahern, MS, MT(ASCP), Associate
Professor of Microbiology, State University of New York
Adirondack
Amy L. Ronneberg, MBA, Chief Executive
Officer, National Marrow Donor Program
Brian Wallach & Sandra Abrevaya, Co-
Founders, I AM ALS
Rene Quashie, JD, Vice President, Digital
Health, Consumer Technology Association
On May 13, 2026, the Subcommittee on Health met in open
markup session and forwarded H.R. 5160, without amendment, to
the full Committee by a voice vote.
On May 21, 2026, the full Committee on Energy and Commerce
met in open markup session and ordered H.R. 5160, as amended,
favorably reported to the House by a record vote of 46 yeas and
0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
reauthorize the C.W. Bill Young Cell Transplantation program
and the National Cord Blood Inventory program through Fiscal
Year 2031.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 5160 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearings were used to develop or consider H.R. 5160:
On April 15, 2026, the Subcommittee on
Health held a legislative hearing on H.R. 5160. The
title of the hearing was ``Healthier America:
Legislative Proposals to Improve Public Health.'' The
Subcommittee received testimony from:
Jamie Ulmer, MA, President and
CEO, Healthcare Network;
Rachel F. Brem, MD, FACR, FSBI,
Co-Founder, Chief Medical Officer, Brem
Foundation to Defeat Breast Cancer and
Professor and Vice-Chair Emeritus, The George
Washington University;
Holly Ahern, MS, MT(ASCP),
Associate Professor of Microbiology, State
University of New York Adirondack;
Amy L. Ronneberg, MBA, Chief
Executive Officer, National Marrow Donor
Program;
Brian Wallach & Sandra Abrevaya,
Co-Founders, I AM ALS; and,
Rene Quashie, JD, Vice
President, Digital Health, Consumer Technology
Association.
On April 21, 2026, the Subcommittee on
Health held a hearing related to H.R. 5150. The title
of the hearing was ``The Fiscal Year 2027 Department of
Health and Human Services Budget.'' The Subcommittee
received testimony from:
The Honorable Robert F. Kennedy,
Jr., Secretary, U.S. Department of Health and
Human Services.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 5160 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides a short title of ``Stem Cell Therapeutic
and Research Reauthorization Act of 2025''.
Section 2. Reauthorization of the C.W. Bill Young Cell Transplantation
Program
Section 2 reauthorizes the C.W. Bill Young Cell
Transplantation Program through Fiscal Year 2031.
Section 3. Cord blood inventory
Section 3 reauthorizes appropriations for the collection
and maintenance of the National Cord Blood Inventory. This
section also updates inventory management parameters to
facilitate maximizing the availability of high-quality cord
blood units that meet applicable clinical and quality
standards.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE
* * * * * * *
PART I--C.W. BILL YOUNG CELL TRANSPLANTATION PROGRAM
* * * * * * *
SEC. 379B. AUTHORIZATION OF APPROPRIATIONS.
For the purpose of carrying out this part, there are
authorized to be [appropriated $31,009,000] appropriated--
(1) $31,009,000 for each of fiscal years 2022
through 2026[.]; and
(2) $33,009,000 for each of fiscal years 2027 through
2031.
* * * * * * *
----------
STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005
* * * * * * *
SEC. 2. CORD BLOOD INVENTORY.
(a) In general.--The Secretary of Health and Human Services
shall enter into contracts with qualified cord blood banks to
assist in the collection and maintenance of the inventory goal
of [at least 150,000 new units of high-quality cord blood] a
sufficient supply, as determined by the Secretary, of high-
quality cord blood units to be made available for
transplantation through the C.W. Bill Young Cell
Transplantation Program and to carry out the requirements of
subsection (b).
(b) Requirements.--The Secretary shall require each recipient
of a contract under this section--
(1) to acquire, tissue-type, test, cryopreserve, and
store donated units of cord blood acquired with the
informed consent of the donor, as determined by the
Secretary pursuant to section 379(c) of the Public
Health Service Act, in a manner that complies with
applicable Federal and State regulations;
(2) to encourage donation from a genetically diverse
population;
(3) to make cord blood units that are collected
pursuant to this section or otherwise and meet all
applicable Federal standards available to transplant
centers for transplantation;
(4) to make cord blood units that are collected, but
not appropriate for clinical use, available for peer-
reviewed research;
(5) to make data available, as required by the
Secretary and consistent with section 379(d)(3) of the
Public Health Service Act (42 U.S.C. 274k(d)(3)), as
amended by this Act, in a standardized electronic
format, as determined by the Secretary, for the C.W.
Bill Young Cell Transplantation Program; and
(6) to submit data in a standardized electronic
format for inclusion in the stem cell therapeutic
outcomes database maintained under section 379A of the
Public Health Service Act, as amended by this Act.
(c) Application.--To seek to enter into a contract under this
section, a qualified cord blood bank shall submit an
application to the Secretary at such time, in such manner, and
containing such information as the Secretary may reasonably
require. At a minimum, an application for a contract under this
section shall include a requirement that the applicant--
(1) will participate in the C.W. Bill Young Cell
Transplantation Program for a period of at least 10
years beginning on the last date on which the recipient
of a contract under this section receives Federal funds
under this section;
(2) will make cord blood units collected pursuant to
this section available through the C.W. Bill Young Cell
Transplantation Program [in perpetuity or] for such
time as determined viable by the Secretary;
(3) will provide a plan to increase cord blood unit
collections at collection sites that exist at the time
of application, assist with the establishment of new
collection sites, or contract with new collection
sites;
(4) will annually provide to the Secretary a plan
for, and demonstrate, ongoing measurable progress
toward achieving self-sufficiency of cord blood unit
collection and banking operations; and
[(5) if the Secretary determines through an
assessment, or through petition by the applicant, that
a cord blood bank is no longer operational or does not
meet the requirements of section 379(d)(4) of the
Public Health Service Act (as added by this Act) and as
a result may not distribute the units, transfer the
units collected pursuant to this section to another
qualified cord blood bank approved by the Secretary to
ensure continued availability of cord blood units.]
(5) if the Secretary determines through an
assessment, or through petition by the applicant, that
a cord blood bank is no longer operational, does not
meet the requirements described in subsection (d)(4),
or does not meet the requirements of section 379(d)(4)
of the Public Health Service Act, and as a result may
not distribute the high-quality units, the Secretary
may transfer the units collected pursuant to this
section to another qualified cord blood bank or entity
approved by the Secretary to ensure continued
availability of high-quality cord blood units.
(d) Duration of Contracts.--
(1) In general.--Except as provided in paragraph (2),
the term of each contract entered into by the Secretary
under this section shall be for a period of at least 10
years beginning on the last date on which the recipient
of a contract under this section receives Federal funds
under this section. The Secretary shall ensure that no
Federal funds shall be obligated under any such
contract after the date that is 5 years after the date
on which the contract is entered into, except as
provided in paragraphs (2), (3), and (4).
(2) Extensions.--The Secretary may extend the period
of funding under a contract under this section to
exceed a period of 5 years if--
(A) the Secretary finds that the inventory
goal described in subsection (a) has not yet
been met;
(B) the Secretary does not receive an
application for a contract under this section
meeting the requirements under subsection (c)
from any qualified cord blood bank that has not
previously entered into a contract under this
section; or
(C) the Secretary determines that the
outstanding inventory need cannot be met by the
qualified cord blood banks under contract under
this section.
(3) Extension eligibility.--A qualified cord blood
bank shall be eligible for a 5-year extension of a
contract awarded under this section, as described in
paragraph (2), provided that the qualified cord blood
bank--
(A) demonstrates a superior ability to
satisfy the requirements described in
subsection (b) and achieves the overall goals
for which the contract was awarded;
(B) provides a plan for how the qualified
cord blood bank will increase cord blood unit
collections at collection sites that exist at
the time of consideration for such extension of
a contract, assist with the establishment of
new collection sites, or contract with new
collection sites; and
(C) annually provides to the Secretary a plan
for, and demonstrates, ongoing measurable
progress toward achieving self-sufficiency of
cord blood unit collection and banking
operations.
[(4) Consideration of best science.--The Secretary
shall take into consideration the best scientific
information available in order to maximize the number
of cord blood units available for transplant when
entering into contracts under this section, or when
extending a period of funding under such a contract
under paragraph (2).]
(4) Consideration of best science.--The Secretary
shall take into consideration current scientific and
clinical information in order to maximize the
availability of high-quality cord blood units meeting
applicable clinical and quality standards for
transplant when entering into contracts under this
section, or when extending a period of funding under
such a contract under paragraph (2).
(5) Consideration of banked units of cord blood.--In
extending contracts pursuant to paragraph (3), and
determining new allocation amounts for the next
contract period or contract extension for such cord
blood bank, the Secretary shall take into account the
number of cord blood units banked in the National Cord
Blood Inventory by a cord blood bank during the
previous contract period, in addition to consideration
of the ability of such cord blood bank to increase the
collection and maintenance of additional, genetically
diverse cord blood units.
(e) Inventory Management.--
(1) In general.--The Secretary shall manage the size
and composition of the National Cord Blood Inventory to
maximize clinical utility, ensure genetic diversity,
and promote the efficient use of resources.
(2) Considerations.--In carrying out paragraph (1),
the Secretary may--
(A) on the Secretary's own initiative or upon
petition by a qualified cord blood bank, make
determinations regarding the continued storage
of cord blood units based on the best available
scientific and clinical evidence; or
(B) prioritize the collection, retention, or
disposition of cord blood units based on
scientific, clinical, or operational
considerations that the Secretary determines to
be relevant.
[(e)] (f) Regulations.--The Secretary may promulgate
regulations to carry out this section.
[(f)] (g) Definitions.--In this section:
(1) The term ``C.W. Bill Young Cell Transplantation
Program'' means the C.W. Bill Young Cell
Transplantation Program under section 379 of the Public
Health Service Act, as amended by this Act.
(2) The term ``cord blood donor'' means a mother who
has delivered a baby and consents to donate the
neonatal blood remaining in the placenta and umbilical
cord after separation from the newborn baby.
(3) The term ``cord blood unit'' means the neonatal
blood collected from the placenta and umbilical cord of
a single newborn baby.
(4) The term ``high quality cord blood unit'' means a
cord blood unit that meets current industry standards
and any requirements of the Food and Drug
Administration.
[(4)] (5) The term ``qualified cord blood bank'' has
the meaning given to that term in section 379(d)(4) of
the Public Health Service Act, as amended by this Act.
[(5)] (6) The term ``Secretary'' means the Secretary
of Health and Human Services.
[(g)] (h) Authorization of Appropriations.--To carry out this
section, there is authorized to be appropriated $23,000,000 for
each of [fiscal years 2022 through 2026] fiscal years 2027
through 2031.
* * * * * * *
[all]